

Diagnostics & Precision Medicine Summit 2016

June 21, 2016

Company Presentation/Poster Application

Company Name	Cancer Genetics, Inc.
Life Sciences Sector	<input checked="" type="checkbox"/> Diagnostics <input type="checkbox"/> Biotech <input type="checkbox"/> Pharmaceuticals <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other (specify):
Commercial Focus/Therapeutic Area	Oncology
Company Description (max 50 words)	<i>Please attach</i>
Company Development/Commercial Stage	Public - NASDAQ:CGIX
Product Name (if applicable)	Focus::Lymphoma™ NGS Panel
Product Description – Include value and advancements that the product brings to Precision Medicine (max 100 words)	<i>Please attach</i>
Funding Status	?
Presentation/Poster Objectives	<input checked="" type="checkbox"/> Partnering <input type="checkbox"/> Funding <input type="checkbox"/> Other (specify):
Contact Name/Title	Jamie Thalmann, Marketing & Communications Manager
Contact Information	Email: jamie.thalmann@cgix.com Phone: 201-528-9200 Address: 201 Route 17 North, 2nd Floor Rutherford, NJ 07070

Thank You to Our Sponsors



Company Description: Cancer Genetics, Inc. (CGI)

CGI is a leader in enabling precision medicine in oncology from bench-to-bedside through the use of oncology biomarkers and molecular testing. We have strong research collaborations with major cancer centers i.e. MSKCC, Cleveland Clinic, Mayo, and NCI. CGI offers comprehensive laboratory services via CLIA/CAP-accredited laboratories in NJ, NC and CA.

Poster Description: ASH 2015

Product: Focus::Lymphoma™ NGS Panel

A 220 gene panel was designed using Nimblegen target capture probes to sequence exonic regions of genes reported to carry somatic mutations in DLBCL, FL, MCL, and CLL. A pilot study showed correlation between variants associated with GCB and non-GCB subtypes, thus validating the clinical robustness of the panel. This panel can be used to assess copy number changes using off-target reads and CNV kit algorithm. Sites of clinically relevant resistance mutations achieve an average coverage high enough to detect low level variants.